Shani Waninger

Summary

• Ph.D. Biochemistry, Johns Hopkins University and over 14 years postdoctoral experience; in depth knowledge of virology drug discovery and development

• 6 years Project Leader of infectious disease drug discovery and development program

• Extensive experience in medical and scientific writing including IND filings, SBIR NIH grants, peer reviewed manuscripts, patent applications, research posters, marketing materials, press releases and research program summaries

• Exemplary managerial, problem solving and communication skills coupled with demonstrated multitasking abilities

• Proven ability to both lead and contribute to crossfunctional teams and deliver on project goals with aggressive timelines

• Established track record for building collaborative relationships with academic investigators, clinicians and key opinion leaders

Experience :

Advanced Brain Monitoring (July 2014 - Present)
Director, Clinical Development

Cosmo Bio USA (December 2010 - December 2012)
Scientific Communication Specialist

• Scientific and technical writing for press release, product descriptions, web site content and advertisements

• Advertisement design for print and banner ads for scientific journals using Adobe CS5

• Cosmo Bio USA company website design and maintenance

• HTML email campaign design and distribution

• Representation of the company at scientific conferences

• Proficiency in Photoshop, Flash, Dreamweaver, Microsoft Office

Adventrx Pharmaceuticals (April 2004 - October 2009)
Associate Director, Research and Development

• Project Team Leader and management of broad spectrum antiviral drug discovery and development programs

• Lead author on SBIR NIH grants, peer reviewed manuscripts, pharm/tox, clinical and CMC section of IND filings, patent applications, research posters, marketing materials and press releases

• Designed and presented infectious disease and oncology research program summaries to pharmaceutical and biotech companies for new business partnerships and licensing opportunities

• Represented the company at national and international infectious disease conferences and presented antiviral research programs

• Established and maintained collaborative relationships with national and international infectious disease KOLs and potential business partners

• Expanded the company’s Intellectual Property portfolio in HIV and human and avian influenza with application to therapeutic treatment of infected patients

• Lead author on press release, IND filings, SBIR NIH grants, peer reviewed manuscripts, patent applications and research program summaries

• Designed, supervised and interpreted screening, efficacy and mechanistic antiviral studies for therapeutics to HIV, human and avian influenza, HCV, WNV and rhinovirus

• Design and monitoring of outsourced pharmacology and toxicology for antiviral and oncology drug candidates

• Design, supervision, execution and interpretation of screening, efficacy and mechanistic antiviral studies on small molecule therapeutics for HIV, human and avian influenza, west nile virus and herpes simplex virus

• Developed assays for higher throughput screening and efficacy studies of antiviral drug candidates

• Implemented and supervised BSL-2 and BSL-3 and trained all personnel

Immusol (April 2000 - April 2004)
Senior Scientist

• Developed and established combinatorial ribozyme libraries and identified novel therapeutic drug targets for HIV, HCV and rhinovirus

• Validated drug targets and identified diverse affected steps in the viral replication cycle using siRNA technology

• Developed and implemented assays for screening and validation of novel therapeutic drug targets

• Characterized the mechanism of identified and validated gene targets through cellular and enzymatic virology methodology

• Led a research group of scientist in discovery of infectious disease drug targets

• Maintained and supervised BSL-3 and trained all BSL-3 scientists

University of California (1997 – 2000)Postdoctoral Fellow

• Isolated HIV Pre-integration Complexes and developed model to study mechanism of nuclear import and integration

• Characterized mechanism of specific steps of HIV integration using radiolabeled DNA fragment substrates corresponding to integration intermediates and purified virally encoded proteins

• Developed a purification method for HIV integrase and integrase fragments

• Created HIV integrase variant virus through site directed mutagenesis, transfection and amplification of virus

• Supervised and trained graduate and undergraduate students in BSL-2 and BSL-3 cell culture and molecular biology studies

Johns Hopkins University (1991 to 1997)
Doctoral Student

Advisor: Dr. John J. Scocca
Thesis Topic: Intasome Assembly during Site Specific Recombination of HP1

• Identified and characterized key mechanistic steps in the integration of a HP1 including protein:protein and protein:DNA interactions through biochemical and molecular biology methods

• Established a collaboration with leading structural scientists at the National Institutes of